The estimated Net Worth of Mark A Sirgo is at least 18.8 百万$ dollars as of 1 July 2022. Mark Sirgo owns over 175,000 units of Biodelivery Sciences International stock worth over 8,128,106$ and over the last 20 years he sold BDSI stock worth over 10,350,301$. In addition, he makes 320,185$ as Vice Chairman of the Board at Biodelivery Sciences International.
Mark has made over 70 trades of the Biodelivery Sciences International stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 175,000 units of BDSI stock worth 43,750$ on 1 July 2022.
The largest trade he's ever made was exercising 1,500,901 units of Biodelivery Sciences International stock on 2 January 2018 worth over 8,390,037$. On average, Mark trades about 52,103 units every 60 days since 2004. As of 1 July 2022 he still owns at least 1,454,044 units of Biodelivery Sciences International stock.
You can see the complete history of Mark Sirgo stock trades at the bottom of the page.
Dr. Mark A. Sirgo Ph.D. serves as Vice Chairman of the Board of the Company. He has served as Chief Executive Officer of ArunA Bio since January 2019. Formerly, he served as our President since January 2005 and Chief Executive Officer since August 2005. He joined our company in August 2004 as Senior Vice President of Commercialization and Corporate Development upon our acquisition of Arius Pharmaceuticals, of which he was a co-founder and Chief Executive Officer. He has also served as our Executive Vice President, Corporate and Commercial Development and our Chief Operating Officer. Dr. Sirgo has over 35 years of experience in the pharmaceutical industry, which includes clinical drug development, marketing, sales, and business development, and executive management positions. Prior to Arius Pharmaceuticals, from 2003 to 2004, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc. Dr. Sirgo served on the Board of Directors of Salix Pharmaceuticals, Inc., from 2008 until its sale in 2015. Dr. Sirgo was added to the Board of Directors of Biomerica, Inc., a diagnostics and therapeutic company, in July 2016 and as Chairman of the Board of RDD Pharma, Ltd., in April 2018.
As the Vice Chairman of the Board of Biodelivery Sciences International, the total compensation of Mark Sirgo at Biodelivery Sciences International is 320,185$. There are 8 executives at Biodelivery Sciences International getting paid more, with Scott Plesha having the highest compensation of 1,503,860$.
Mark Sirgo is 66, he's been the Vice Chairman of the Board of Biodelivery Sciences International since 2017. There are 1 older and 13 younger executives at Biodelivery Sciences International. The oldest executive at Biodelivery Sciences International is William Watson, 69, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 4509 CREEDMOOR ROAD, SUITE 201, RALEIGH, NC, 27612.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over 111,671,776$ worth of Biodelivery Sciences International stock and bought 1,813,177 units worth 5,352,510$ . The most active insiders traders include International, L.P. Elliott、Associates, L.P. Elliott、Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of 420,648$. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth 29,811$.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: